Coronavirus Update: Roche's Actemra Shows No Benefit In Early COVID-19 Pneumonia Study
Plus Synairgen Expands Home-based Interferon Trial
Executive Summary
Roche's Actemra was identified early on in the pandemic as a possible treatment for patients with COVID-19 induced pneumonia. As larger studies await read-out, data from an Italian study disappoints.